DaShenLin Pharmaceutical Group Co (603233.SS) Stock Price
DaShenLin Pharmaceutical Group Co Price
Revenue has compounded at 17.8% per year over the past 13 years to 27.50 B CNY. Earnings per share have grown at 17.7% per year over the last 13 years. DaShenLin Pharmaceutical Group Co's net margin stands at 4.5%, broadly stable from 4.7% several years earlier. DaShenLin Pharmaceutical Group Co currently offers a dividend yield of about 3.47%. The payout ratio is around 60% of earnings. The dividend has grown at 16.5% per year over the past 7 years. Analysts set a median price target of 24.48 CNY, implying 30.6% above the current price. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus.
DaShenLin Pharmaceutical Group Co stock price
DaShenLin Pharmaceutical Group Co business model & stock analysis
Frequently asked questions about DaShenLin Pharmaceutical Group Co
Analysts currently set an average price target of 24.77 CNY for the DaShenLin Pharmaceutical Group Co stock (median: 24.48 CNY), implying +32.1 % versus the latest price. The consensus is based on 14 analyst ratings.
DaShenLin Pharmaceutical Group Co Analyst Price Targets 2026
14 analysts currently rate the DaShenLin Pharmaceutical Group Co stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect DaShenLin Pharmaceutical Group Co to generate revenue of 29.42 B CNY and earnings per share of 1.30 CNY.
DaShenLin Pharmaceutical Group Co Analyst Price Targets 2026
Converted at the current exchange rate, the DaShenLin Pharmaceutical Group Co share trades at 2.49 EUR (18.75 CNY).
The DaShenLin Pharmaceutical Group Co share (603233.SS) is listed on 1 stock exchanges, including: Shanghai (603233.SS).
The expected revenue of DaShenLin Pharmaceutical Group Co is 29.42 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of DaShenLin Pharmaceutical Group Co is 1.47 B CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of DaShenLin Pharmaceutical Group Co is currently 14.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DaShenLin Pharmaceutical Group Co stock.
The price-to-sales ratio (P/S) of DaShenLin Pharmaceutical Group Co is currently 0.72. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DaShenLin Pharmaceutical Group Co stock.
The Eulerpool Quality Score for DaShenLin Pharmaceutical Group Co is 8/10.
The ISIN of DaShenLin Pharmaceutical Group Co is CNE100002RG2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of DaShenLin Pharmaceutical Group Co is 603233.SS. The ticker symbol is used to trade DaShenLin Pharmaceutical Group Co shares on the stock exchange.
DaShenLin Pharmaceutical Group Co stock
DaShenLin Pharmaceutical Group Co Peer Group
DaShenLin Pharmaceutical Group Co Ticker
DaShenLin Pharmaceutical Group Co FIGI
All fundamentals and in-depth analysis of DaShenLin Pharmaceutical Group Co
Our stock analysis for DaShenLin Pharmaceutical Group Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DaShenLin Pharmaceutical Group Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.